Loading...
•
Sep 30, 2022
Palatin Technologies Q1 2023 Earnings Report
Reported financial results for the fiscal first quarter ended September 30, 2022.
Key Takeaways
Palatin Technologies reported a net loss of $8.3 million for the quarter ended September 30, 2022. Net product revenue increased 13% over the prior quarter and 445% over the comparable quarter in 2021. Cash and cash equivalents were $21.2 million as of September 30, 2022.
Vyleesi net product revenue increased 13% and prescriptions dispensed increased 17%, over the prior quarter.
Phase 3 pivotal study of PL9643 in patients with Dry Eye Disease is ongoing.
Phase 2 clinical study of oral PL8177 in patients with Ulcerative Colitis has commenced.
Closed on a $10 Million Registered Direct Offering.
Palatin Technologies
Palatin Technologies
Forward Guidance
Palatin currently expects an operating cash runway through calendar year 2023.